Riverhead Capital Management LLC Has $182,000 Stake in Omnicell, Inc. (OMCL)
Riverhead Capital Management LLC grew its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 76.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,230 shares of the company’s stock after purchasing an additional 1,830 shares during the period. Riverhead Capital Management LLC’s holdings in Omnicell were worth $182,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Arizona State Retirement System lifted its holdings in shares of Omnicell by 0.5% during the second quarter. Arizona State Retirement System now owns 19,384 shares of the company’s stock valued at $835,000 after purchasing an additional 100 shares during the last quarter. Monroe Bank & Trust MI lifted its holdings in shares of Omnicell by 0.3% during the first quarter. Monroe Bank & Trust MI now owns 34,831 shares of the company’s stock valued at $1,416,000 after purchasing an additional 116 shares during the last quarter. Texas Permanent School Fund lifted its holdings in shares of Omnicell by 0.5% during the first quarter. Texas Permanent School Fund now owns 26,756 shares of the company’s stock valued at $1,088,000 after purchasing an additional 122 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its holdings in shares of Omnicell by 2.6% during the first quarter. Municipal Employees Retirement System of Michigan now owns 8,340 shares of the company’s stock valued at $339,000 after purchasing an additional 210 shares during the last quarter. Finally, Juncture Wealth Strategies LLC lifted its holdings in shares of Omnicell by 1.3% during the second quarter. Juncture Wealth Strategies LLC now owns 30,065 shares of the company’s stock valued at $1,296,000 after purchasing an additional 373 shares during the last quarter. 96.35% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/riverhead-capital-management-llc-has-182000-stake-in-omnicell-inc-omcl/1600311.html.
Shares of Omnicell, Inc. (NASDAQ OMCL) opened at 51.05 on Friday. The company has a 50-day moving average price of $50.04 and a 200 day moving average price of $43.64. The stock’s market capitalization is $1.91 billion. Omnicell, Inc. has a 52 week low of $30.35 and a 52 week high of $52.70.
Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, July 27th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.02. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The firm had revenue of $180.90 million during the quarter, compared to analysts’ expectations of $174.08 million. During the same period in the previous year, the firm earned $0.38 earnings per share. The company’s revenue was up 4.6% on a year-over-year basis. Analysts forecast that Omnicell, Inc. will post $1.30 earnings per share for the current fiscal year.
Several equities research analysts have recently commented on the company. Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. Benchmark Co. upped their target price on Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a report on Tuesday, September 5th. BidaskClub downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies reaffirmed a “hold” rating and set a $40.00 target price on shares of Omnicell in a report on Sunday, July 30th. Finally, Dougherty & Co upped their target price on Omnicell from $45.00 to $49.00 and gave the company a “buy” rating in a report on Friday, July 28th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $51.57.
In other Omnicell news, EVP Robin Gene Seim sold 9,780 shares of the business’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $48.97, for a total value of $478,926.60. Following the completion of the transaction, the executive vice president now directly owns 55,896 shares of the company’s stock, valued at $2,737,227.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Randall A. Lipps sold 10,625 shares of the business’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $52.00, for a total value of $552,500.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 180,562 shares of company stock valued at $8,914,801. Insiders own 3.77% of the company’s stock.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.